Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Mesoblast Limited (MESO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Mesoblast Limited — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Mesoblast Limited trades at $15.44 (market cap $2.00B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 19.9× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | MESO | |
|---|---|---|
Market Cap | $39.89B | $2.00B |
Sector | Health | Technology |
52-Week High | $491.22 | $20.96 |
52-Week Low | $278.09 | $10.96 |
Enterprise Value | $38.15B | $2.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
MESO trades at $15.44, up 4.11% today, with a bullish technical signal from moving averages but overbought RSI near 89. The company reported a net loss of $102.14 million in 2025 despite an 80.52% gross margin, while recent news highlights Ryoncil revenue growth and FDA progress for its heart failure treatment, signaling a transition to commercial operations.
The outlook is cautiously optimistic, driven by product commercialization and pipeline advancements, but high cash burn and negative margins pose significant risks. Analyst consensus leans buy (45% of ratings), yet the stock's elevated P/S ratio of 30.52 demands careful valuation assessment amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
